特发性膜性肾病的发病率逐年增高，占原发性肾病综合症的30-40%，因特发性膜性肾病的预后在疾病发现之时无法进行准确判断，为治疗方案的选择带来困难，中医药是治疗膜性肾病的有效方法，越来越受到重视。三芪口服液是全国名老中医杨霓芝教授发明并应用于膜性肾病治疗的有效药物，临床应用近二十年获得患者好评。项目将针对三芪口服液治疗膜性肾病的机制及其药效物质基础展开研究，研究将分为两部分：首先，通过分子生物学技术与现代组学技术相结合，在分子-细胞-整体水平对三芪口服液治疗膜性肾病的药效机制进行研究；其次，通过构建三芪口服液体内/体外化学指纹图谱，结合细胞及动物模型探讨三芪口服液的PK-PD特点，结合系统生物学技术进行关联分析，阐明三芪口服液治疗膜性肾病的“量-时-效”的动态PK-PD过程，进而阐释三芪口服液治疗膜性肾病的药效物质基础。通过本研究以期全面阐释三芪口服液治疗膜性肾病的机制，为临床应用提供依据。

Idiopathic membranous nephropathy (IMN) is one of the most common causes (occupies about 30-40%) of primary nephrotic syndrome and its morbidity increased year by year. Due to its uncertain prognosis, it's quite difficult to decide the therapeutic schedule. Traditional Chinese medicine (TCM) is an effective method for the treatment of IMN and has received more and more attention. San Qi oral solution (SQ), which was designed and developed by Professor Yang Nizhi, is an effective formulated product to treat IMN and has been utilized for about 20 years in clinic. It is effective, and has been favored by many patients. Our study aims to elucidate the mechanisms of effects of SQ on treating IMN and its pharmacodynamic material foundation. Firstly, we would use molecular biology techniques combined with modern omics technology to study pharmacodynamics and the underlying mechanism. Secondly, we would compare the finger-print of SQ in vitro/vivo, and study the pharmacokinetics-pharmacodynamics (PK-PD) of SQ by using both animal and cell models, combined with correlation analysis of systems biology, thus illuminating the "dose-time-effect" of dynamic PK-PD in SQ treating IMN. Through this study, we try to comprehensively elucidate the mechanisms of effects of SQ on treating IMN and to provide theoretical support for clinical application.